Albiglutide, a long-acting GLP-1 mimetic: pharmacodynamics, pharmacokinetics, safety and tolerability in subjects with type 2 diabetes

被引：0

作者：

Stewart, M. W. ^{[1
]}

Matthews, J. ^{[2
]}

De Boever, E. H. ^{[3
]}

Dobbins, R. L. ^{[2
]}

Hodge, R. J. ^{[5
]}

Walker, S. E. ^{[4
]}

Holland, C. H. ^{[6
]}

Bush, M. A. ^{[7
]}

机构：

[1] GlaxoSmithKline Inc, Alternat Dev Program, King Of Prussia, PA USA

[2] GlaxoSmithKline Inc, Clin Pharmacol Discovery Med, Res Triangle Pk, NC USA

[3] GlaxoSmithKIine, BioPharm Drug Discovery, King Of Prussia, PA USA

[4] GlaxoSmithKline Inc, Discovery Biometr, Res Triangle Pk, NC USA

[5] GlaxoSmithKline Inc, CSSO, Res Triangle Pk, NC USA

[6] GlaxoSmithKline Inc, Clin Immunol, King Of Prussia, PA USA

[7] GlaxoSmithKline Inc, Clin Pharmacokinet, Res Triangle Pk, NC USA

来源：

DIABETOLOGIA | 2008年 / 51卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

870

引用

页码：S347 / S347

页数：1

共 50 条

[1] Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide (Syncria®), a long-acting GLP-1 mimetic, in subjects with type 2 diabetes
Stewart, Murray W.
Matthews, Jessica
De Boever, Erika H.
Dobbins, Robert L.
Hodge, Rebecca J.
Walker, Susan E.
Holland, Claire H.
Bush, Mark A.
DIABETES, 2008, 57 : A154 - A154
[2] Pharmacokinetics, safety, and tolerability of albiglutide (Syncria®), a long-acting GLP-1 mimetic, in healthy volunteers
Stewart, Murray W.
Matthews, Jessica
De Boever, Erika H.
Dobbins, Robert L.
Holland, Claire H.
Hodge, Rebecca J.
Gutierrez, Maria J.
Walker, Susan E.
Bush, Mark A.
DIABETES, 2008, 57 : A155 - A155
[3] Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus
Seino, Yutaka
Nakajima, Hiromu
Miyahara, Hajime
Kurita, Takashi
Bush, Mark A.
Yang, Fred
Stewart, Murray W.
CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (12) : 3049 - 3057
[4] Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Albiglutide, a Long-Acting Glucagon-Like Peptide-1 Mimetic, in Patients with Type 2 Diabetes
Matthews, Jessica E.
Stewart, Murray W.
De Boever, Erika H.
Dobbins, Robert L.
Hodge, Rebecca J.
Walker, Susan E.
Holland, M. Claire
Bush, Mark A.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (12): : 4810 - 4817
[5] Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects
Bush, M. A.
Matthews, J. E.
De Boever, E. H.
Dobbins, R. L.
Hodge, R. J.
Walker, S. E.
Holland, M. C.
Gutierrez, M.
Stewart, M. W.
DIABETES OBESITY & METABOLISM, 2009, 11 (05): : 498 - 505
[6] Albiglutide: clinical overview of a long-acting GLP-1 receptor agonist in the treatment of Type 2 diabetes
Setji, Tracy
Feinglos, Mark
EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2013, 8 (03) : 229 - 238
[7] The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men
Agerso, H
Jensen, LB
Elbrond, B
Rolan, P
Zdravkovic, M
DIABETOLOGIA, 2002, 45 (02) : 195 - 202
[8] The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men
H. Agersø
L. B. Jensen
B. Elbrønd
P. Rolan
M. Zdravkovic
Diabetologia, 2002, 45 : 195 - 202
[9] The Gastrointestinal Adverse Event Profile of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes
Stewart, Murray W.
Reusch, Jane E. B.
Bush, Mark A.
Yang, Fred
Rosenstock, Julio
DIABETES, 2009, 58 : A161 - A161
[10] Population Pharmacokinetics of Albiglutide (Syncria®), a Long-Acting GLP-1 Receptor Agonist, Supports Weekly or Less Frequent Dosing in Type 2 Diabetes
Bush, Mark A.
Stewart, Murray W.
Rosenstock, Julio
Yang, Fred
DIABETES, 2010, 59 : A163 - A163

← 1 2 3 4 5 →